Physician profile
Nelson Moy
NPI 1891951406
$5,070.70
in general payments reported to CMS, 2019-2025
37 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $353 · 2022: $17.30 · 2023: $310 · 2024: $940 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,644.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $751.54 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $453.27 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $303.87 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $287.00 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $180.76 | 2019-2025 | |
| Genzyme Corporation | $164.31 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.27 | 2019-2020 | |
| Allergan, INC. | $122.99 | 2019 | |
| Eisai INC. | $120.90 | 2019 | |
| Medical Device Business Services, INC. | $110.94 | 2019 | |
| Qol Medical, LLC | $82.59 | 2024-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $69.03 | 2025 | |
| Urogen Pharma, INC. | $67.63 | 2025 | |
| Pfizer INC. | $54.44 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $50.18 | 2019-2020 | |
| Janssen Biotech, INC. | $46.62 | 2023 | Stelara, Simponi, Simponi Aria |
| Ardelyx, INC. | $44.30 | 2024-2025 | Ibsrela |
| Amag Pharmaceuticals, INC. | $40.26 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $31.57 | 2019 | |
| Exact Sciences Corporation | $29.85 | 2024-2025 | Cologuard Collection Kit |
| Echosens North America, INC. | $27.21 | 2025 | Fibroscan |
| Tolmar, INC. | $25.51 | 2025 | Jatenzo, Eligard |
| Romark Laboratories, Lc | $23.55 | 2019 | |
| Braintree Laboratories, INC. | $23.04 | 2020 | |
| Daiichi Sankyo INC. | $20.63 | 2020 | |
| Organon LLC | $20.33 | 2024 | |
| Celgene Corporation | $19.31 | 2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.69 | 2025 | Givlaari |
| Amgen INC. | $17.46 | 2020 | |
| Nestle Healthcare Nutrition INC. | $17.30 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.09 | 2019 | |
| Cook Medical LLC | $13.26 | 2019 | |
| Merck Sharp & Dohme LLC | $11.95 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.54 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Moy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.